Results from Merck’s Vorinostat phase 1 trial on lymphoma

Published on February 5, 2013 at 6:54 AM · No Comments

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase 1 clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic acid) in combination with another round of commonly used second-line drugs resulted in a 70 percent response rate, including several patients whose lymphoma cells disappeared entirely.

According to Ajay Gopal, M.D., associate member of the Fred Hutch Clinical Research Division and corresponding author of the paper, published online in the British Journal of Haematology, the study results open the way to potentially solve the dilemma of how to effectively treat patients when modern cancer drugs fail after the first try. And, he said, it sets the stage for using a new class of drugs called histone-deacetylase inhibitors (HDAC), of which Vorinostat is one, to sensitize tumor cells to the cancer-killing effects of chemotherapy.

Patients treated in the trial had several types of lymphoma, however the best responses were seen in those who had Hodgkin and diffuse large B-cell lymphomas, two of the most aggressive types that typically require a stem cell transplant to cure if they are not cured after the first line of treatment. Knocking back the cancer raises the likelihood for a successful transplant.

"The better the response, the better the outcome will be when patients proceed to a stem cell transplant designed to cure them of their disease," said Elizabeth Budde, M.D., Ph.D., a research associate in the Fred Hutch Clinical Research Division and first author of the study.

The researchers noted that while the current front-line chemotherapy drugs are the most effective yet against lymphomas, patients who relapse after receiving them are less likely to achieve long-term, disease-free survival when current second-line or "salvage" therapies are applied. This is because the cancers develop resistance to the drugs or the tumor's biology changes in some way to reduce their effectiveness.

Lymphoma refers to a group of cancers that strike the lymphatic system, which is a key part of the immune system. Lymphomas are broadly classified as either Hodgkin or non-Hodgkin. Some lymphomas are highly curable; others require complex treatment.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post